ArticleFrontiers in pharmacology2012
Transport of Aflatoxin M(1) in Human Intestinal Caco-2/TC7 Cells.
Article in Frontiers in pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Modulation of intestinal functions following mycotoxin ingestion: meta-analysis of published experiments in animals.Toxins · 2013Pooled it
- Aflatoxin M1 decreases the expression of genes encoding tight junction proteins and influences the intestinal epithelial integrity.Mycotoxin research · 2023Article
- Human Breast Milk Contamination with Aflatoxins, Impact on Children's Health, and Possible Control Means: A Review.International journal of environmental research and public health · 2022Review
- Metabolic Disruption by Naturally Occurring Mycotoxins in Circulation: A Focus on Vascular and Bone Homeostasis Dysfunction.Frontiers in nutrition · 2022Review
- A Tissue-Engineered Tracheobronchial In Vitro Co-Culture Model for Determining Epithelial Toxicological and Inflammatory Responses.Biomedicines · 2021Article
- Aflatoxin B1 and Aflatoxin M1 Induce Compromised Intestinal Integrity through Clathrin-Mediated Endocytosis.Toxins · 2021Article
- Fungal Toxins and Host Immune Responses.Frontiers in microbiology · 2021Review
- Mycotoxins: Biotransformation and Bioavailability Assessment Using Caco-2 Cell Monolayer.Toxins · 2020Review
- PNU-282987 Attenuates Intestinal Epithelial Barrier Dysfunction in LPS-Induced Endotoxemia.Inflammation · 2020Article
- Repeated exposure to aerosolized graphene oxide mediates autophagy inhibition and inflammation in a three-dimensional human airway model.Materials today. Bio · 2020Article
- Chronic and Acute Toxicities of Aflatoxins: Mechanisms of Action.International journal of environmental research and public health · 2020Review
- Article
- Differential Transcriptome Responses to Aflatoxin B₁ in the Cecal Tonsil of Susceptible and Resistant Turkeys.Toxins · 2019Article
- Article
- The intestinal barrier as an emerging target in the toxicological assessment of mycotoxins.Archives of toxicology · 2017Review
- Leaky Gut and Mycotoxins: Aflatoxin B1 Does Not Increase Gut Permeability in Broiler Chickens.Frontiers in veterinary science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aflatoxin M(1) (AFM(1)) is a hydroxylated metabolite of aflatoxin B(1) (AFB(1)). After it is formed, it is secreted in the milk of mammals. Despite the potential risk of human exposure to AFM(1), data reported in literature on the metabolism, toxicity, and bioavailability of this molecule are limited and out of date. The aim of the present research was to study the absorption profile of AFM(1) and possible damage to tight junctions (TJ) of the intestinal Caco-2/TC7 clone grown on microporous filter supports. These inserts allowed for the separation of the apical and basolateral compartments which correspond to the in vivo lumen and the interstitial space/vascular systems of intestinal mucosa respectively. In this study, the Caco-2/TC7 cells were treated with different AFM(1) concentrations (10-10,000 ng/kg) for short (40 min) and long periods of time (48 h). The AFM(1) influx/efflux transport and effects on TJ were evaluated by measuring trans-epithelial electrical resistance and observing TJ protein (Zonula occludens-1 and occludin) localization. The results showed that: (i) when introduced to the apical and basolateral compartments, AFM(1) was poorly absorbed by the Caco-2/TC7 cells but its transport across the cell monolayer occurred very quickly (P(app) value of 105.10 ± 7.98 cm/s × 10(-6)). (ii) The integrity of TJ was not permanently compromised after exposure to the mycotoxin. Viability impairment or barrier damage did not occur either. The present results contribute to the evaluation of human risk exposure to AFM(1), although the AFM(1) transport mechanism need to be clarified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.